ArticleProstate cancer and prostatic diseases2010
Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay.
Article in Prostate cancer and prostatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 61 citations in OpenAlex.
- Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.Journal of personalized medicine · 2021Review
- Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis.Cancers · 2020Review
- Mitochondria in cancer.Cell stress · 2020Review
- Comparative analysis of camelid mitochondrial genomes.Journal of genetics · 2019Article
- A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.International journal of molecular sciences · 2019Review
- Promise and Implementation of Proteomic Prostate Cancer Biomarkers.Diagnostics (Basel, Switzerland) · 2018Review
- A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA 'grey zone'.World journal of urology · 2018Article
- Clinical and Novel Biomarkers in the Management of Prostate Cancer.Current treatment options in oncology · 2018Review
- Mitochondrial mutations drive prostate cancer aggression.Nature communications · 2017Article
- Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management.Oncotarget · 2017Review
- Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Current genomics · 2017Review
- Tissue-based biomarkers in prostate cancer.Expert review of precision medicine and drug development · 2017Article
- Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population.American health & drug benefits · 2016Article
- Article
- PSA and beyond: alternative prostate cancer biomarkers.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.Biomarkers in cancer · 2016Review
- Addressing the need for repeat prostate biopsy: new technology and approaches.Nature reviews. Urology · 2015Review
- Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.World journal of urology · 2015Article
- Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.World journal of urology · 2015Review
- Active surveillance and focal therapy for low-intermediate risk prostate cancer.Translational andrology and urology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several cancers are characterized by large-scale mtDNA deletions. We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies. This study was to assess the clinical value of this deletion in predicting re-biopsy outcomes. We used a quantitative polymerase chain reaction assay to measure the levels of the deletion in individual negative needle biopsies from 101 patients who had a repeat biopsy within a year with known outcomes. Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion. The Ct cutoff at 31 gave a sensitivity and specificity of 84 and 54%, respectively, with the area under a receiver-operating characteristics curve of 0.749. The negative predictive value was 91%. The assay was able to predict the presence of a missed tumor in 17 out of 20 men a year before diagnosis. This ancillary test appears to identify men who do not require a repeat biopsy with a high degree of certainty. The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.